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Peripheral arterial occlusive disease (PAOD) results from atherosclerosis of large and medium peripheral arteries,
as well as the aorta, and has many risk factors, including smoking, diabetes, hypertension, and hyperlipidemia.
PAOD often coexists with coronary artery disease and cerebrovascular disease. Cross-matching a population-based
list of Icelandic patients with PAOD who had undergone angiography and/or revascularization procedures with a
genealogy database of the entire Icelandic nation defined 116 extended families containing 272 patients. A ge-
nomewide scan with microsatellite markers revealed significant linkage to chromosome 1p31 with an allele-sharing
LOD score of 3.93 ( ). We designate this locus as “PAOD1.” Subtracting 35 patients with a history55Pp 1.04 # 10
of stroke increased the LOD score to 4.93. This suggests that, although PAOD and other vascular diseases share
risk factors, genetic factors specific to subtypes of vascular disease may exist.
Introduction
Atherosclerosis is the pathology underlying several of
humankind’s most lethal diseases, such as myocardial
infarction (MI) and stroke. PAOD shares the risk factors
of those atherosclerotic diseases, especially smoking, di-
abetes, hypertension, and hyperlipidemia (Dormandy et
al. 1999; Hooi et al. 1999). However, PAOD represents
atherosclerosis of the large and medium arteries of the
limbs, particularly to the lower extremities, and includes
the aorta and iliac arteries. It often coexists with coro-
nary artery disease and cerebrovascular disease. Clini-
cally significant lesions may gradually narrow the pe-
ripheral arteries, leading to pain, on walking, that is
usually relieved by rest (claudication); ischemic ulcers;
gangrene; and, sometimes, limb amputation. Medical
therapy is generally ineffective, but operations bypassing
or replacing the lesion with artificial or venous grafts
improve blood flow distally, at least until the grafts be-
come restenosed (Haustein 1997).
Here we present data on the mapping of a locus for
PAOD. This is the first example of linkage to a specific
chromosomal location reported for this disease. For this
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study, we recruited patients with PAOD whose diag-
nosis had been angiographically and/or surgically con-
firmed. This phenotype represents the 20% of the pa-
tients with PAOD who have the most severe disease
based on epidemiological studies in other populations
(Dormandy et al. 1999).
Subjects and Methods
Population and Genealogy
This study was approved by the Data Protection Com-
mission of Iceland and the National Bioethics Commit-
tee of Iceland. Informed consent was obtained from all
patients and their relatives whose DNA samples were
used in the linkage scan (see the deCODE Genetics Web
site for an example of the informed consent form). The
original population-based lists of patients with PAOD
covering the years 1980–1995 were derived from the
two major hospitals in Iceland. All patients had under-
gone angiography, and 85% had angioplasty and/or vas-
cular surgery. Those undergoing vascular procedures for
trauma were excluded.
A comprehensive genealogy database established at
deCODE Genetics was used to cluster the patients in
pedigrees (Gulcher and Stefansson 1998). Each version
of the computerized genealogy database is reversibly en-
crypted by the Data Protection Commission of Iceland
before arriving at the laboratory (Gulcher et al. 2000).
The database uses a patient list, with encrypted personal
identifiers, as input and uses recursive algorithms to find
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all ancestors in the database who are related to any
member on the input list, within a given number of gen-
erations. The cluster function then searches for ancestors
who are common to any two or more members of the
input list.
Microsatellite Markers and Genotyping
The marker order and positions for the framework
mapping set were obtained from the Marshfield genetic
map, except for a three-marker putative inversion on
chromosome 8 (Jonsdottir et al. 2000; Yu et al. 2000;
Giglio et al. 2001). The DNA samples were genotyped
using nearly 1,000 fluorescently labeled primers. We
have developed a microsatellite screening set based in
part on the ABI Linkage Marker (version 2) screening
set and the ABI Linkage Marker (version 2) intercalating
set in combination with 1500 custom-made markers. All
markers were extensively tested for robustness, ease of
scoring, and efficiency in 4# multiplex PCRs. The PCR
amplifications were set up, run, and pooled on Perkin
Elmer/Applied Biosystems 877 Integrated Catalyst Ther-
mocyclers, with a similar protocol for each marker. The
reaction volume used was 5 ml, and, for each PCR, 20
ng of genomic DNA was amplified in the presence of 2
pmol of each primer, 0.25 U AmpliTaq Gold, 0.2 mM
dNTPs, and 2.5 mM MgCl2 (buffer was supplied by
manufacturer). The PCR conditions used were 95C for
10 min, then 37 cycles of 94C for 15 s, 55C for 30 s,
and 72C for 1 min. The PCR products were supple-
mented with the internal size standard, and the pools
were separated and detected on Applied Biosystems
model 377 Sequencer, by use of Genescan version 3.0
peak-calling software. Alleles were called automatically
with the TrueAllele program (see Cybergenetics Web
site), and the program DecodeGT was used to fraction-
ate according to quality and to edit the called genotypes
(Palsson et al. 1999). At least 180 Icelandic control sub-
jects were genotyped to derive allelic frequencies.
Statistical Methods for Linkage Analysis
In our analyses, we used multipoint, affected-only al-
lele-sharing methods to assess the evidence for linkage.
All relatives who did not have an angiogram or surgery
for PAOD were considered to have “unknown” status.
All results were obtained using the program Allegro
(Gudbjartsson et al. 2000). We used the scoringSpairs
function (Whittemore and Halpern 1994; Kruglyak et
al. 1996) and the exponential allele-sharing model (Kong
and Cox 1997) to generate the relevant statistics with 1
df. When combining the family scores to obtain an over-
all score, instead of weighting the families equally, which
is the default method of Genehunter (Kruglyak et al.
1996), or weighting the affected pairs equally, we used
a weighting scheme that is halfway between the two on
the log scale; our family weights are the geometric means
of the weights of the two schemes. Although not iden-
tical, this weighting scheme tends to give results similar
to those of the scheme proposed by Weeks and Lange
(1988) as an extension of a weighting scheme of Hodge
(1984) designed for sibships. We computed the P value
two different ways and report the less significant one.
The first P value was computed based on large-sample
theory; is approximately distrib-Z p 2 log (10)LODlr e
uted as a standard normal random variable under the
null hypothesis of no linkage (Kong and Cox 1997).
Because of the concern with small-sample behavior, we
computed a second P value by comparing the observed
LOD score to its complete data-sampling distribution
under the null hypothesis (Gudbjartsson et al. 2000).
When a data set consists of more than a few families,
as is the case here, these two P values tend to be very
similar. To ensure that the result was a true reflection of
the information contained in the material, for us to con-
sider a linkage result significant, it was required not only
that the P value be ! (Lander and Kruglyak52 # 10
1995) but also that the information content in the region
was85%. For the families in this study, an information
content of 85% corresponded to a marker density of
approximately one marker per centimorgan. The infor-
mation measure we used has been defined elsewhere (Ni-
colae 1999) and has been implemented in Allegro. This
measure is closely related to a classical measure of in-
formation (Dempster et al. 1977), having the property
that it is between 0, if the marker genotypes are com-
pletely uninformative, and 1, if the genotypes determine
the exact amount of allele sharing by descent among the
affected relatives.
After obtaining a significant allele-sharing LOD score,
in an attempt to understand the contribution of this
susceptibility locus, we fitted a range of parametric mod-
els to the data. Even when fitting parametric models, we
performed affected-only analyses, in the sense that an
individual is classified either as affected or as having
unknown disease status. As a consequence, only ratios
of penetrances are relevant. We fitted a range of single-
locus dominant, additive, and multiplicative models
(Risch 1990). With a complex disease such as PAOD,
none of these simple models are likely to be exactly true
and the effect of a gene and its variants can only be
reliably determined after the at-risk variant, or variants,
are identified. However, by calculating the correspond-
ing contribution to the sibling recurrence-risk ratio, the
fitted parametric models do provide some rough idea as
to how much the gene is contributing to the familial
clustering of the disease.
To assess whether the increase in LOD score resulting
from subtracting the 35 patients with PAOD who also
had stroke would be likely to occur by chance, we se-
lected 1,000 random sets of 35 patients whose status we
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Figure 1 Comparison of marker order and genetic distances.
Arrows indicate flips in marker order between the two maps. Asterisks
(*) denote two markers flipped in the UCSC December 2000 freeze
(corrected in the UCSC April 2001 freeze).
then changed to “unknown” in an analysis. The P value
we present is the fraction of the 1,000 simulations that
produced a LOD score increase at the peak locus equal
to or greater than that which we observed by changing
the affection status of the stroke patients to “unknown.”
We used the same method to assess subtraction of the
38 patients with PAOD who also had MI. There, how-
ever, we assess the significance of the decrease in LOD
score that results by looking at the fraction of the sim-
ulations that produced a LOD-score decrease greater or
equal to that which we observed by changing the affec-
tion status of the MI patients to “unknown.”
Physical and Genetic Mapping
For the locus region, a combination of data from co-
incident hybridizations of BAC membranes by use of a
high density of STSs, and the Finger Printing Contig
(FPC) database was used to build large contigs of BACs
from the RPCI-11 library provided by Pieter deJong
(Children’s Hospital Oakland Research Institute). BAC
contigs were generated by a method that combines co-
incident hybridization, versus the RPCI-11 BAC library,
with data mining and the FPC program (see Wellcome
Trust Sanger Institute Web site). Hybridizations were
performed using primers from markers in the region of
interest according to their location in the Weizmann In-
stitute Unified Database. To close the gaps, new markers
were generated from BAC end sequences.
High-resolution genetic mapping was used (1) to an-
chor and place in order contigs found by physical map-
ping and (2) to obtain accurate intermarker distances
for the correctly ordered markers (see fig. 1 for marker
orders and distances used). Data from 112 Icelandic nu-
clear families (sibships with their parents, containing two
to seven siblings) were analyzed together with the nu-
clear families available within the PAOD pedigrees. For
the purpose of genetic mapping, the 112 nuclear families
alone provided 588 meioses, and the total number of
meioses available for mapping was 11,000. By compar-
ison, the Marshfield genetic map was constructed on the
basis of 182 meioses. The large number of meiotic events
within our families provides the ability to map markers
to a resolution of 1.0 cM or better. Using a modification
of the Allegro program, we then applied the expectation-
maximization algorithm (Dempster et al. 1977) to our
data to estimate the genetic distances between markers.
Combining this information with the physical map re-
sulted in a highly reliable order of markers and better
estimates of intermarker distances within the peak re-
gion, both of which are important for an accurate link-
age analysis (Halpern and Whittemore 1999; Daw et al.
2000).
Results
We used our genealogy database together with a pop-
ulation-based list of 1,745 patients who had undergone
angiography and/or surgery for PAOD to define families
of patients with PAOD. Our study was focused on pa-
tients who were related to other patients by six or fewer
meiotic events. This article reports the results of our
linkage scan on a total of 272 patients and 612 relatives
within 116 families. Figure 2 exhibits two of the larger
families used in the analysis, as well as an example of
a family in which a patient with PAOD is related to
another patient with PAOD who also had stroke. Our
genome-scan results are displayed in figure 3. The most
prominent linkage was found to chromosome 1p with
a LOD score of 2.95, although other LOD scores 11.5
also occur on 13q and 18q. Additional microsatellite
markers were genotyped and mapped for the chromo-
some 1p peak region. When our map was used, the mul-
tipoint analysis increased the LOD score on chromo-
some 1 to 3.93 ( ) (fig. 4). In contrast,5Pp 1.04 # 10
when the Marshfield map was used, the LOD score was
2.83. The peak is centered on marker D1S2895, with
markers D1S411 and D1S2855, telomeric and centrom-
eric, respectively, defining a drop of 1 in LOD score from
the peak. We designate this locus as “PAOD1.”
Our genetic map for 19 markers in the peak region,
along with the publicly available Marshfield genetic
map, is displayed in figure 1. The Marshfield map differs
from our map both in the order of a number of markers,
for which Marshfield has no resolution, and in the ge-
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Figure 2 Three families used in the linkage study of PAOD. Two
of the families, A and B, have positive LOD scores at the chromosome
1p31 locus, whereas the cousin pair in family C contributes negatively.
Sex indicators have been shuffled for some individuals in the top two
generations, and unaffected siblings of patients are not shown, to pro-
tect privacy. The blackened squares and circles represent men and
women, respectively, who are affected with PAOD. The checkered
square represents a patient with PAOD who also had stroke. The
slashed symbols represent deceased individuals.
Table 1
Risk Factors and Demographics of Patients in the Study
RISK FACTORa
% OF PATIENT GROUP
All ( )bnp 272 with NPL 11 ( )np 75
Hyperlipidemia 33.8 39.2
Hypertension 51.8 48.6
Diabetes 9.9 9.5
Smokingc 77.6 85
a Risk factors were self reported.
b Of the 272 patients, 169 (62%) were male and 103
(38%) were female. Mean age was 70.8 years.
c Including both current and past smoking.
netic distance between markers. At the time of our sub-
mission, the December 2000 freeze of the University of
California Santa Cruz (UCSC) draft assembly of the
human DNA sequence was available. Our order of
markers agreed with the public sequence, except for the
two markers that are indicated in figure 1. The April
2001 freeze (released June 2001) corrected the order of
these two markers but changed the orders of two other
pairs (not shown in figure 1). The August 2001 freeze
agrees with the order we have.
Some demographic information and the fraction of
patients with several risk factors are given in table 1,
for the entire patient set. For the risk factors, we have
also displayed the fractions for the set of patients in
families with nonparametric linkage (NPL) scores 1
(the patients in these families show an excess of sharing
genetic material identical by descent over what would
be expected simply because of their relationship). There
does not appear to be any substantial shifting in the
pattern of risk factors for the patients from these fam-
ilies. This suggests that this PAOD locus is not a locus
for these risk factors.
PAOD is often associated with other forms of ath-
erosclerosis, such as cerebrovascular disease and coro-
nary artery disease, and many of the patients we studied
also had a history of stroke and/or MI. When we rean-
alyzed our data—after defining those 35 patients with
PAOD (13% of the total) who also had history of stroke
as having unknown disease status, instead of affected
status—the LOD score on chromosome 1 increased to
4.93. This increase in the LOD score due to subtraction
of the stroke patients is statistically significant (Pp
) (fig. 4). When we subtracted the 38 patients with.019
PAOD who also had MI (14%; designating their affec-
tion status as “unknown”), the LOD score decreased
to 2.95. However, this decrease was not statistically sig-
nificant ( ) and may simply reflect the reductionPp .577
of the material.
In an attempt to understand the contribution of this
locus to the population, we tried fitting a variety of
parametric models, dominant, additive, or multiplica-
tive. For each of these models, we were able to achieve
a LOD score 14.0 at this locus. For example, a dominant
model assuming that the at-risk allele has a frequency
of 14% and the penetrance of a noncarrier is 0 gives a
LOD score of 4.26. For this dominant model, 47 of the
116 families give a positive LOD score; of these, 38
families have LOD scores 10.1, and three families have
Figure 3 Full genome scan of all affected family members, by use of nearly 1,000 microsatellite markers. The multipoint LOD score is on the Y-axis, and distance (in centimorgans) from the
p-terminus of the chromosome is on the X-axis.
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Figure 4 Multipoint allele-sharing LOD score of chromosome
1 with extra microsatellite markers within PAOD1. The solid line
represents the results of all 272 patients with PAOD. The dashed line
represents the results of defining affecteds as PAOD without stroke.
LOD scores between 0.4 and 0.7. The three families,
A, B, and C, in figure 2 gave LOD scores of 0.68, 0.62,
and 0.12 respectively, for this model. Note that, even
for a family with a negative LOD score, some or all of
the patients can carry the at-risk allele since they could
have inherited it from different sources. A multiplicative
model assuming that the at-risk allele has a frequency
of 20% and that there is a seven-fold increase in risk
for every at-risk allele carried gives a LOD score of 4.23.
These dominant and multiplicative models correspond
to sibling recurrence-risk ratios of 2.37 and 2.54.
Discussion
In this study of PAOD, we defined the phenotype as
surgically corrected and/or angiographically docu-
mented PAOD, a definition that has many advantages.
This decreases the subjectivity sometimes encountered
when defining PAOD based on the patient’s history of
intermittent claudication. This also eliminates the need
of relying on the ankle-brachial blood-pressure ratio,
which may vary from observer to observer (Jeelani et al.
2000). Since only ∼20%–25% of patients with PAOD
ever go on to have angiography and surgery, this group
represents those who are more severely affected by the
disease.
The lack of prominent linkage to PAOD1 in our
stroke linkage study (in this issue) suggests that a gene
at this PAOD locus may confer a specific predisposition
to PAOD, rather than to stroke or to PAOD in those
patients with stroke. This increase in LOD score with
the removal of stroke patients suggests that there are
other strong genetic and/or environmental factors that
contribute to both PAOD and stroke. A more accurate
understanding of the contribution of PAOD1 to PAOD
will have to await its isolation.
Although some have predicted that examining the
consequences of atherosclerosis, as we did in this study,
rather than its underlying risk factors, would not yield
sufficient power to detect genes predisposing individuals
to this multifactorial common disease, we have shown
that the genealogic approach can indeed yield significant
linkage. This study suggests that there is both overlap
and independence between genetic factors for the major
manifestations of atherosclerosis, specifically PAOD
and stroke. It further suggests that, at least in Iceland,
there exist genes with major influence on one’s risk of
PAOD. Because no correlation was observed between
patients contributing to the LOD score and vascular
risk factors such as hyperlipidemia, hypertension, and
diabetes, PAOD1 is unlikely to be simply a hyperten-
sion, diabetes, or hyperlipidemia locus. This suggests
that additional genetic factors may affect the pathogen-
esis of atherosclerosis—either directly, in the arterial
wall where it takes place, or indirectly, through medi-
ators in the blood, such as mononuclear cells, platelets,
or coagulation factors.
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